Follow
David Finlay
David Finlay
Postdoctoral Fellow, University of Otago
Verified email at otago.ac.nz - Homepage
Title
Cited by
Cited by
Year
Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity
M Soethoudt, U Grether, J Fingerle, TW Grim, F Fezza, L De Petrocellis, ...
Nature communications 8 (1), 13958, 2017
3082017
Terpenoids from cannabis do not mediate an entourage effect by acting at cannabinoid receptors
DB Finlay, KJ Sircombe, M Nimick, C Jones, M Glass
Frontiers in pharmacology 11, 510858, 2020
902020
s signalling of the CB1 receptor and the influence of receptor number
DB Finlay, EE Cawston, NL Grimsey, MR Hunter, A Korde, VK Vemuri, ...
British Journal of Pharmacology 174 (15), 2545-2562, 2017
842017
GPR18 undergoes a high degree of constitutive trafficking but is unresponsive to N-Arachidonoyl Glycine
DB Finlay, WR Joseph, NL Grimsey, M Glass
PeerJ 4, e1835, 2016
772016
Cannabinoid CB1 and CB2 receptor-mediated arrestin translocation: species, subtype, and agonist-dependence
MS Ibsen, DB Finlay, M Patel, JA Javitch, M Glass, NL Grimsey
Frontiers in pharmacology 10, 350, 2019
712019
Do toxic synthetic cannabinoid receptor agonists have signature in vitro activity profiles? A case study of AMB-FUBINACA
DB Finlay, JJ Manning, MS Ibsen, CE Macdonald, M Patel, JA Javitch, ...
ACS chemical neuroscience 10 (10), 4350-4360, 2019
482019
100 years of modelling ligand–receptor binding and response: A focus on GPCRs
DB Finlay, SB Duffull, M Glass
British journal of pharmacology 177 (7), 1472-1484, 2020
472020
Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists
M Patel, JJ Manning, DB Finlay, JA Javitch, SD Banister, NL Grimsey, ...
Biochemical Pharmacology 175, 113871, 2020
462020
Biased agonism at the cannabinoid receptors–evidence from synthetic cannabinoid receptor agonists
M Patel, DB Finlay, M Glass
Cellular Signalling 78, 109865, 2021
312021
Pharmacological selection of cannabinoid receptor effectors: Signalling, allosteric modulation and bias
JJ Manning, HM Green, M Glass, DB Finlay
Neuropharmacology 193, 108611, 2021
282021
Model‐free and kinetic modelling approaches for characterising non‐equilibrium pharmacological pathway activity: Internalisation of cannabinoid CB1 receptors
X Zhu, DB Finlay, M Glass, SB Duffull
British Journal of Pharmacology 176 (14), 2593-2607, 2019
242019
Real-time measurement of cannabinoid receptor-mediated cAMP signaling
MR Hunter, DB Finlay, CE Macdonald, EE Cawston, NL Grimsey, M Glass
Methods in enzymology 593, 43-59, 2017
172017
An evaluation of the operational model when applied to quantify functional selectivity
X Zhu, DB Finlay, M Glass, SB Duffull
British Journal of Pharmacology 175 (10), 1654-1668, 2018
162018
Evaluation of the profiles of CB1 cannabinoid receptor signalling bias using joint kinetic modelling
X Zhu, DB Finlay, M Glass, SB Duffull
British Journal of Pharmacology 177 (15), 3449-3463, 2020
142020
In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018
TF Gamage, DG Barrus, RC Kevin, DB Finlay, TW Lefever, PR Patel, ...
Pharmacology Biochemistry and Behavior 193, 172918, 2020
122020
A novel allosteric modulator of the cannabinoid CB1 receptor ameliorates hyperdopaminergia endophenotypes in rodent models
CA Mielnik, KS Sugamori, DB Finlay, HHA Thorpe, M Schapira, ...
Neuropsychopharmacology 46 (2), 413-422, 2021
112021
Signaling-specific inhibition of the CB1 receptor for cannabis use disorder: phase 1 and phase 2a randomized trials
M Haney, M Vallée, S Fabre, S Collins Reed, M Zanese, G Campistron, ...
Nature Medicine 29 (6), 1487-1499, 2023
102023
Delineating the interactions between the cannabinoid CB2 receptor and its regulatory effectors; β‐arrestins and GPCR kinases
M Patel, C Matti, NL Grimsey, DF Legler, JA Javitch, DB Finlay, M Glass
British journal of pharmacology 179 (10), 2223-2239, 2022
92022
Defining Steric Requirements at CB1 and CB2 Cannabinoid Receptors Using Synthetic Cannabinoid Receptor Agonists 5F-AB-PINACA, 5F-ADB-PINACA, PX-1 …
J Markham, E Sparkes, R Boyd, S Chen, JJ Manning, D Finlay, F Lai, ...
ACS Chemical Neuroscience 13 (8), 1281-1295, 2022
82022
Development of 3-(4-chlorophenyl)-1-(phenethyl) urea analogues as allosteric modulators of the cannabinoid type-1 receptor: RTICBM-189 is brain penetrant and attenuates …
T Nguyen, TF Gamage, DB Finlay, AM Decker, TL Langston, D Barrus, ...
Journal of medicinal chemistry 65 (1), 257-270, 2021
82021
The system can't perform the operation now. Try again later.
Articles 1–20